SCOTTSDALE, Ariz. July 17, 2013 The Side-Out Foundation's breast cancer pilot study, led by the Translational Genomics Research Institute (TGen), Translational Drug Development (TD2) and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling.
Specifically, 52 percent of patients with advanced breast cancer received clinical benefit meaning their disease was controlled for a longer time when their cancer was treated based on addressing the abnormal proteins in their tumor, according to the study conducted at the Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and TGen.
Each patient's treatment was "personalized," meaning that the therapy they received was based on their individual tumor biology.
"This study demonstrates the feasibility of personalized cancer treatment, and shows that this approach merits further investigation in future studies," said Gayle Jameson, Nurse Practitioner at Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the study's Principal Investigator.
"The success of this pilot study will lead to a larger study and hopefully greater clinical benefit for more patients with advanced breast cancer," said Jameson, who presented the results of the study in June at the 2013 American Society of Clinical Oncology (ASCO) in Chicago.
Due to the overwhelmingly positive results, a new study incorporating additional technology for tumor analysis, Side-Out II, will open at the Virginia G. Piper Cancer Center Clinical Trials in the near future for patients with advanced breast cancer.
"The success of our pilot proof-of-concept study has established a firm launching pad for the upcoming Side-Out II study, which involves a more in-depth investigation of tumor biology with an expanded repertoire of tests to direct personalized treatment," said Dr. Jasgit Sachdev, M.D., a bre
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute